Efecto de la inoculación con hongos formadores de micorrizas arbusculares sobre plántulas de caucho

Hongos formadores de micorrizas arbusculares (HFMA) obtenidos a partir de suelos caucheros se multiplicaron en plantas de Lolium sp., con 73% de colonización radical luego de 4 meses. Se obtuvieron 7 morfotipos de HFMA, con los cuales se inocularon dos grupos de plántulas de Hevea brasiliensis: 1) producidas in vivo a partir de semilla; 2) producidas in vitro por rescate de embrión, para determinar efectos sobre mortalidad, crecimiento, micorrización y contenido de fósforo foliar. Los niveles de colonización por HFMA para las plántulas obtenidas in vitro e in vivo fueron de 12,6% y de 44,7 %, respectivamente. La biomasa media total acumulada por las plántulas producidas in vitro fue de 0,41 y de 1,40 g por las procedentes del material in vivo, en comparación con los controles no inoculados, los cuales acumularon 0,37 y 0,40 g, respectivamente. El tratamiento con HFMA disminuyó la mortalidad en las plántulas obtenidas in vitro, aunque no tuvo un efecto significativo sobre el contenido de fósforo foliar. La respuesta del crecimiento de las plántulas inoculadas fue diferente dependiendo del origen del material vegetal y del tipo de inóculo (nativo o no nativo). La simbiosis entre HFMA y H. brasiliensis se desarrolló en condiciones controladas de crecimiento, aunque su avance dependió del estado de desarrollo de la plántula. No obstante, influyó en el crecimiento y en la disminución de la mortalidad de las plántulas, lo que abre la posibilidad de utilizarla como alternativa de inoculación en las fases tempranas de obtención del material vegetal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. Funding: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D’Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

EFECTO DE LA INOCULACIÓN CON HONGOS FORMADORES DE MICORRIZAS ARBUSCULARES SOBRE PLÁNTULAS DE CAUCHO

Hongos formadores de micorrizas arbusculares (HFMA) obtenidos a partir de suelos caucheros se multiplicaron en plantas de Lolium sp., con 73% de colonización radical luego de 4 meses. Se obtuvieron 7 morfotipos de HFMA, con los cuales se inocularon dos grupos de plántulas de Hevea brasiliensis: 1) producidas in vivo a partir de semilla; 2) producidas in vitro por rescate de embrión, para determinar efectos sobre mortalidad, crecimiento, micorrización y contenido de fósforo foliar. Los niveles de colonización por HFMA para las plántulas obtenidas in vitro e in vivo fueron de 12,6% y de 44,7 %, respectivamente. La biomasa media total acumulada por las plántulas producidas in vitro fue de 0,41 y de 1,40 g por las procedentes del material in vivo, en comparación con los controles no inoculados, los cuales acumularon 0,37 y 0,40 g, respectivamente. El tratamiento con HFMA disminuyó la mortalidad en las plántulas obtenidas in vitro, aunque no tuvo un efecto significativo sobre el contenido de fósforo foliar. La respuesta del crecimiento de las plántulas inoculadas fue diferente dependiendo del origen del material vegetal y del tipo de inóculo (nativo o no nativo). La simbiosis entre HFMA y H. brasiliensis se desarrolló en condiciones controladas de crecimiento, aunque su avance dependió del estado de desarrollo de la plántula. No obstante, influyó en el crecimiento y en la disminución de la mortalidad de las plántulas, lo que abre la posibilidad de utilizarla como alternativa de inoculación en las fases tempranas de obtención del material vegetal

Impact of culture conditions on root growth and mycorrhization of Hevea brasiliensis in vitro

Hevea brasiliensis is cultivated worldwide for the production of natural rubber. In vitro studies on the mycorrhization of this tree are essential to increase the knowledge about the biology of the symbiosis, and to validate the utilization of arbuscular mycorrhizal fungi (AMF) in rubber nurseries. The objective of this thesis was to study the effect of the culture conditions on the association between the AMF Rhizophagus irregularis and H. brasiliensis plantlets growing in an autotrophic in vitro culture system. The combination of high atmospheric CO2 with addition of MES and activated charcoal to the culture medium improved root growth and colonization. The pruning of the taproot did not significantly impact these parameters. None of the treatments accelerated the formation of new roots or their colonization, suggesting that other factors (e.g. plant genetics and physiology) may be involved. We hypothesized that the delay in root colonization may be related to root exudates produced by H. brasiliensis. To test this hypothesis, we placed Medicago truncatula seedlings in an actively growing extraradical mycelium network of R. irregularis, in close vicinity of a H. brasiliensis plantlet. We observed a decrease in the root colonization of M. truncatula, and a negative effect on the metabolic activity of the AMF, suggesting that roots exudates containing antifungal molecules were produced. The experimental system adapted during this thesis offers large opportunities for molecular and physiological studies that could contribute to elucidate the factors (e.g. plant secondary metabolism) that are regulating the first steps of the symbiosis.(AGRO 3) -- UCL, 201

Effect of activated charcoal and pruning of the taproot on the in vitro mycorrhization of Hevea brasiliensis Müll. Arg.

In vitro mycorrhization of Hevea brasiliensis under autotrophic culture conditions is a promising methodology to produce plantlets adapted to overcome stresses during acclimatization. However, to succeed in the in vitro production of mycorrhizal plantlets, root production and subsequent colonization by the mycorrhizal fungus need to be optimized. Plantlets of H. brasiliensis clone PB 260 were grown in contact with the extraradical mycelium network of the arbuscular mycorrhizal fungus Rhizophagus irregularis MUCL 41833. Addition of activated charcoal to the medium and pruning of the taproot were evaluated for their effects on root growth and colonization. None of the treatments stimulated the early formation of new roots. However, total root length, total root colonization, and production of arbuscules and intraradical spores/vesicles were significantly higher in plantlets grown in the presence of activated charcoal (especially after 13 wk of culture). In contrast, total root colonization was significantly lower in the pruned plantlets, while total root length and arbuscule formation were not affected. None of the treatments affected activities of succinate dehydrogenase and alkaline phosphatase measured in the extraradical mycelium of the fungus. It appeared that the addition of activated charcoal to the culture medium favored root growth and mycorrhization of rubber plantlets under in vitro culture conditions, while taproot pruning did not favor these parameters. © 2014 The Society for In Vitro Biology

Hevea brasiliensis and Urtica dioica impact the in vitro mycorrhization of neighbouring Medicago truncatula seedlings

Hevea brasiliensis is a mycotrophic tree for which root colonization by arbuscular mycorrhizal fungi (AMF) under in vitro or pot culture conditions can take several weeks. The reason for this slow colonization is still unknown, but the exudation of antifungal compounds such as hevein by the roots may be one of the causes. Here, the root colonization of Medicago truncatula, a highly mycotrophic plant, was assessed after 12 days of growth in the extraradical mycelium network of the AMF Rhizophagus irregularis in close vicinity of H. brasiliensis plantlets or Urtica dioica seedlings (also known to synthesize antifungal compounds of the hevein family). We hypothesized that a negative impact on the root colonization of a M. truncatula seedling developing close to H. brasiliensis and U. dioica may give indirect proofs for the exudation of inhibitory molecules. The percentages of total root colonization of M. truncatula were 30.1 % lower in the presence of H. brasiliensis than in the control plants, and 29.1 % lower in presence of U. dioica. The abundance of arbuscules in the roots of M. truncatula was also lower in plants grown in presence of H. brasiliensis plantlets than in the control plants. Similarly, the succinate dehydrogenase and the phosphatase activities measured in the extraradical mycelium of R. irregularis were significantly lower in the presence of both plants, compared with the controls. No root colonization was observed in H. brasiliensis and U. dioica within the time-frame of the experiments. The low root colonization of M. truncatula when grown in the presence of rubber or stinging nettle suggested the exudation of diffusible molecules which could also explain the delayed root colonization of H. brasiliensis and the absence of colonization of U. dioica. © 2013 Springer Science+Business Media Dordrecht

In vitro mycorrhization of the rubber tree Hevea brasiliensis Müll Arg

In vitro cultivation systems of arbuscular mycorrhizal fungi are useful tools to study the interaction between plants and their fungal symbiont, and also to develop new biotechnologies. Plantlets of the latex-producing species Hevea brasiliensis clone PB 260 were grown in a dense extraradical mycelium network of the arbuscular mycorrhizal fungus Rhizophagus irregularis MUCL 41833 developed from a mycelium donor plant (Medicago truncatula A17). The factors indole-3-butyric acid (IBA), 2-morpholineoethanesulfonic acid monohydrate (MES) buffer, and carbon dioxide (CO2) were tested on root development and colonization by the fungus. No colonization was observed in the presence of plantlets pre-treated with IBA. The highest levels of root colonization were obtained when plantlets were mycorrhized under a high CO2 concentration (1,000 μmol mol-1) with MES (10 mM) added to the growth medium. Widespread root colonization (with presence of arbuscules, intraradical mycelium, and spores/vesicles) was predominantly observed in newly produced roots. Therefore, it appears essential to improve root initiation and growth for improving in vitro mycorrhization of H. brasiliensis. We demonstrated the potential of the "mycelium donor plant" in vitro culture system to produce colonized H. brasiliensis plantlets before their transfer to ex vitro conditions. © 2013 The Society for In Vitro Biology